Onco Wiki / Bandera roja

CML chronic phase with Hasford (EURO) high risk — supports 2nd-generation TKI 1L (dasatin...

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDRF-HASFORD-HIGH
TipoSeñal de alerta
Situaciónreviewed 2026-04-27 | pending_clinical_signoff
EnfermedadesDIS-CML
FuentesSRC-ELN-CML-2020 SRC-ESMO-CML-2017 SRC-NCCN-MPN-2025

Origen de la bandera roja

DefiniciónCML chronic phase with Hasford (EURO) high risk — supports 2nd-generation TKI 1L (dasatinib / nilotinib / bosutinib) over imatinib; comparable rationale to Sokal-high
Dirección clínicaintensificar
Categoríapuntuación de riesgo
Algoritmo de cambiosALGO-CML-1L

Lógica de activación

{
  "any_of": [
    {
      "finding": "cml_hasford_risk",
      "value": "high"
    },
    {
      "finding": "cml_euro_risk",
      "value": "high"
    },
    {
      "comparator": ">",
      "finding": "cml_hasford_score",
      "threshold": 1480
    }
  ],
  "type": "composite_score"
}

Notas

Hasford / EURO score (Hasford 1998) refined Sokal by adding eosinophils and basophils; high-risk = >1480. Hasford-high and Sokal-high overlap substantially but identify slightly different subsets. ELN 2020 recognizes both alongside the newer ELTS but prefers ELTS for treatment-free remission planning. Direction `intensify` to 2nd-gen TKI 1L; co-fires with RF-SOKAL-HIGH and the existing RF-CML-HIGH-RISK-ELTS. The CML-1L algorithm picks the 2nd-gen track as long as comorbidity flags don't de-escalate.

Utilizado por

Algoritmos

Señal de alerta